Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Opinion|Videos|February 27, 2026
Fred Saad, MD, highlights phase 1 study of 225Ac-PSMA-Trillium in mCRPC
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Fact checked by: Hannah Clarke
Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.
Advertisement
In this video, Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study, assessing the investigational alpha-emitting radioligand therapy 225Ac-PSMA-Trillium (BAY 3563254) in patients with metastatic castration-resistant prostate cancer (mCRPC). These results were presented at the
Saad is a professor and chief of urology at University of Montreal Hospital Center.
Advertisement
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: September 2026
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
5